MAX-4 is under clinical development by Maxinovel Pharmaceuticals and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MAX-4’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MAX-4 overview

MAX-4 is under development for the treatment of myelodysplastic syndrome, acute myelocytic leukemia, metastatic colorectal cancer, relapsed/refractory acute myeloid leukemia, solid tumors, gastric cancer, small-cell lung cancer and adenocarcinoma of the gastroesophageal junction. The drug candidate is formulated as a capsule and administered through the oral route. It acts by targeting FMS like tyrosine kinase 3 (FLT3) and fibroblast growth factor receptor (FGFR).

Maxinovel Pharmaceuticals overview

Maxinovel Pharmaceuticals is a biotechnology company that specializes in disease areas characterized by high mortality and high morbidity with no effective treatment. The company is headquartered in China.

For a complete picture of MAX-4’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.